AbCellera Biologics Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$3.61
+$0.02 (+0.45%) 4:00 PM ET
After hours$3.70
+$0.09 (+2.62%) 8:57 AM ET
Prev closePrevC$3.59
OpenOpen$3.47
Day highHigh$3.62
Day lowLow$3.37
VolumeVol5,039,228
Avg volAvgVol4,511,663
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.08B
P/E ratio
-7.36
FY Revenue
$75.13M
EPS
-0.49
Gross Margin
100.00%
Sector
Healthcare
AI report sections
BULLISH
ABCL
AbCellera Biologics Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+50% (Above avg)
Vol/Avg: 1.50×
RSI
55.19(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.01 Signal: 0.01
Short-Term
+0.05 (Strong)
MACD: -0.13 Signal: -0.18
Long-Term
+0.00 (Strong)
MACD: -0.17 Signal: -0.18
Intraday trend score
72.00
LOW46.00HIGH77.00
Latest news
ABCL•12 articles•Positive: 1Neutral: 1Negative: 0
NeutralThe Motley Fool• Jesterai
Prelude Cuts Q2 Losses and Costs 13%
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
Mentioned as a continued collaboration partner with no significant new developments
PositiveGlobeNewswire Inc.• Delveinsight
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.
ABCLABSITWSTTMOantibody discoverybiologicsmonoclonal antibodiestherapeutic development
Sentiment note
Highlighted as a notable company in the antibody discovery market with innovative approaches
ABCL earnings call for the period ending March 31, 2024.
ABCLearningscall-transcripts
UnknownZacks Investment Research• Zacks Equity Research
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ABCLRNA
UnknownZacks Investment Research• Zacks Equity Research
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CYTKABCL
UnknownZacks Investment Research• Zacks Equity Research
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABCL earnings call for the period ending December 31, 2023.
ABCLearningscall-transcripts
UnknownZacks Investment Research• Zacks Equity Research
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ABCL
UnknownZacks Investment Research• Zacks Equity Research
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
XAIRABCL
UnknownZacks Investment Research• Zacks Equity Research
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
Techne (TECH) delivered earnings and revenue surprises of -4.76% and 1.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Healthcare stocks have underperformed in 2023, but that is expected to change this year.
HUMCNCHALOABCLinvesting
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
